Login / Signup

Inhibition of the RANKL with denosumab has no effect on circulating markers of atherosclerosis in women with postmenopausal osteoporosis: a pilot study.

Cristiana CiprianiSara PiemonteLuciano ColangeloViviana De MartinoDaniele DiacintiFederica FerroneValentina PiazzollaValeria FassinoLuciano NiedduSalvatore MinisolaJessica Pepe
Published in: Endocrine (2020)
24-m treatment with denosumab has no effect on the circulating markers of atherosclerosis in women with postmenopausal osteoporosis. Fluctuation of serum ICAM-1, CD40L, MMPs, FBG and hs-CRP can be ascribed to perturbation of immunological mechanisms stimulated by denosumab and zoledronic acid.
Keyphrases
  • bone mineral density
  • postmenopausal women
  • body composition
  • cardiovascular disease
  • giant cell
  • type diabetes
  • toll like receptor
  • combination therapy